Patient Access for Pancreatic Cancer Testing

Patient Access for Pancreatic Cancer Testing

The Avantect Pancreatic Cancer Test offers the chance to detect pancreatic cancer early in high-risk patients such as those aged ≥50 with newly diagnosed type 2 diabetes. Talk to your healthcare provider about the test if you’re 50 or older and you think you might be at high risk for pancreatic cancer.

Step 1.

Your healthcare provider orders the test with a test requisition form.

Step 2.

You take a completed form to the person who will draw your blood. You do not need to fast.

Step 3.

We will make the results available to your health care provider within 2 weeks of receiving your sample at our laboratory.

ClearNote Health believes that health equity begins with equal access to patient care across all patient communities. We support those who are uninsured or underinsured, and we offer a discounted price to patients choosing a self-pay option. Financial assistance will be offered through a quick, confidential, over-the-phone, income-based needs assessment.

Our Customer Success Team will review coverage options and offer support based on each patient’s needs. For patient-specific information regarding out-of-pocket costs, including copays, coinsurance, and deductibles, please call our Customer Success Team at +1 833-258-7827.


Good-faith estimates


Uninsured patient financial assistance


HSAs and FSAs accepted


Self-pay patient rate


Individualized payment plans

Important information

The Avantect Pancreatic Cancer Test is an early detection test. The test does not establish a diagnosis of pancreatic cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of pancreatic cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all pancreatic cancers will be detected. Some patients with pancreatic cancer may have a “Signal not detected” result. Some patients without pancreatic cancer may have a “Signal detected” result. False-negative and false-positive results are possible. A “Signal not detected” result does not guarantee that no pancreatic cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient’s blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost.

The test was developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and has not been cleared or approved by the US Food and Drug Administration (FDA).

References and notes

  1. ClearNote Health, data on file.